2024
Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes
Kiwan A, Kewan T, Xu M, Siddon A, Girardi M, Sethi T, Foss F. Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes. Blood 2024, 144: 4440-4440. DOI: 10.1182/blood-2024-205144.Peer-Reviewed Original ResearchGene copy number alterationsAssociated with poor OSAbsolute lymphocyte countFluorescence in situ hybridization panelAssociated with worse OSCirculating tumor cellsFluorescence in situ hybridizationOverall survivalCopy number alterationsT cell receptorPoor OSSurvival outcomesTumor cellsMedian OSCox proportional hazardsBlood involvementATM deletionArid1a deletionT cellsElevated absolute lymphocyte countMedian absolute lymphocyte countAssociated with better OSMedian age of patientsMultivariate CPH modelZEB1 deletionReal World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3LymphomaClinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas
Swallow M, Micevic G, Zhou A, Carlson K, Foss F, Girardi M. Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas. Cancers 2024, 16: 3087. PMID: 39272944, PMCID: PMC11394026, DOI: 10.3390/cancers16173087.Peer-Reviewed Original ResearchT-cell lymphomaPrimary cutaneous gamma/delta T-cell lymphomaSubcutaneous panniculitis-like T-cell lymphomaLymphoproliferative disordersMycosis fungoidesCD8+ cutaneous T-cell lymphomasCutaneous gamma/delta T-cell lymphomaPanniculitis-like T-cell lymphomaGamma/delta T-cell lymphomaCytotoxic T-cell lymphomaT-cell lymphoproliferative disorderAbnormal T-cell populationCutaneous T-cell lymphomaCytotoxic molecule expressionT cell populationsIndicator of prognosisAppropriate treatment planCD8-positiveAggressive entityLymphomatoid papulosisHistological variantsHistopathological differentiationTreatment algorithmCD8Clinical manifestationsEnhanced intratumoral delivery of immunomodulator MPLA via hyperbranched polyglycerol-coated biodegradable nanoparticles
Chang J, Shin K, Lewis J, Suh H, Lee J, Damsky W, Xu S, Bosenberg M, Saltzman W, Girardi M. Enhanced intratumoral delivery of immunomodulator MPLA via hyperbranched polyglycerol-coated biodegradable nanoparticles. Journal Of Investigative Dermatology 2024 PMID: 39122142, DOI: 10.1016/j.jid.2024.07.019.Peer-Reviewed Original ResearchMonophosphoryl lipid ATumor microenvironmentImmunomodulatory agentsStimulation of anti-tumor immune responseEfficacy of monophosphoryl lipid AT-helper (Th)1 responsesAnti-tumor immune responseTumor-draining lymph nodesToxicity associated with systemic administrationImmune responseModel of malignant melanomaAgonist monophosphoryl lipid ABiodegradable nanoparticlesImmunogenic tumor microenvironmentAntitumor immune responseDraining lymph nodesSystemic side effectsNatural killer cellsGradual drug releaseKiller cellsAntitumor efficacyMalignant melanomaImproved survivalLymph nodesChemotherapeutic agentsLB931 Treatment of chronic graft-versus-host disease with combination extracorporeal photopheresis and the ROCK2 inhibitor belumosudil can reverse sclerodermatous changes
Swallow M, Chang J, Carlson K, Odell I, Girardi M. LB931 Treatment of chronic graft-versus-host disease with combination extracorporeal photopheresis and the ROCK2 inhibitor belumosudil can reverse sclerodermatous changes. Journal Of Investigative Dermatology 2024, 144: s163. DOI: 10.1016/j.jid.2024.06.1104.Peer-Reviewed Original Research572 Development of immunotherapies targeting TCR-Vβ2 for treatment of cutaneous T cell lymphoma
Ren J, Liao X, Lewis J, Li D, Chang J, Swallow M, Lee J, Qu R, Carlson K, Foss F, Girardi M. 572 Development of immunotherapies targeting TCR-Vβ2 for treatment of cutaneous T cell lymphoma. Journal Of Investigative Dermatology 2024, 144: s100. DOI: 10.1016/j.jid.2024.06.588.Peer-Reviewed Original ResearchChart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019
Girardi M, Carlson K, Huang X, Corman S, Edmundson P, Schmier J, Kale H, Raina R, Foss F. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019. Journal Of Dermatological Treatment 2024, 35: 2360568. PMID: 38852942, DOI: 10.1080/09546634.2024.2360568.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsExtracorporeal photopheresisResponse rateClinical outcomesMonths of ECP treatmentMedian time to responseReal-world treatment patternsECP initiationLymph node involvementStage IV diseaseAdvanced-stage diseaseT-cell lymphomaTime to responseEffective treatment optionPercentage of patientsChart review studyIV diseaseSezary syndromeNode involvementConcomitant therapySystemic therapyMedian ageMycosis fungoidesChart reviewSyringotropic mycosis fungoides with clinical and histologic features of necrobiosis lipodica diabeticorum
Torres-Piwinski M, Carlson K, Panse G, Girardi M. Syringotropic mycosis fungoides with clinical and histologic features of necrobiosis lipodica diabeticorum. JAAD Case Reports 2024 DOI: 10.1016/j.jdcr.2024.02.029.Peer-Reviewed Original ResearchGeneration and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
Ren J, Liao X, Lewis J, Chang J, Qu R, Carlson K, Foss F, Girardi M. Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy. Nature Communications 2024, 15: 519. PMID: 38225288, PMCID: PMC10789731, DOI: 10.1038/s41467-024-44786-2.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityDonor T cellsT cellsAdeno-associated virus transductionHealthy donor T cellsHost-versus-graft reactivityEnhanced antibody-dependent cellular cytotoxicityCAR-T cellsGraft-versus-hostT cell killingT-cell malignanciesMalignant T cellsNormal T-cellT cell receptorOff-target toxicityPre-existing immunoreactivityCAR-TDisease relapseCellular cytotoxicityVirus transductionCurrent treatmentPersister killingFc engineeringB2MIn vivo
2023
FISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical Outcomes
Avery J, Kim R, Cheng W, Foss F, Girardi M. FISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical Outcomes. JID Innovations 2023, 3: 100212. PMID: 37674691, PMCID: PMC10477749, DOI: 10.1016/j.xjidi.2023.100212.Peer-Reviewed Original ResearchSignal transducerGene copy number variationActivator of transcriptionCopy number variationsGene copy number alterationsGenomic basisCopy number alterationsRelevant genesGenomic sequencingNumber variationsFISH panelNumber alterationsDe novoCost-effective panelFISH resultsAbnormal FISH resultsActivatorGene panelTranscriptionLeukemic cutaneous T-cell lymphomaCutaneous T-cell lymphomaGenesSequencingT-cell lymphomaDeletion1091 Improving the anti-tumor efficacy of immunomodulator MPLA via biodegradable nanoparticle delivery
Chang J, Shin K, Lewis J, Suh H, Bosenberg M, Saltzman W, Girardi M. 1091 Improving the anti-tumor efficacy of immunomodulator MPLA via biodegradable nanoparticle delivery. Journal Of Investigative Dermatology 2023, 143: s187. DOI: 10.1016/j.jid.2023.03.1103.Peer-Reviewed Original ResearchNanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment
Chang J, Yu B, Saltzman W, Girardi M. Nanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment. JID Innovations 2023, 3: 100197. PMID: 37205301, PMCID: PMC10186617, DOI: 10.1016/j.xjidi.2023.100197.Peer-Reviewed Original ResearchA case of bullous lesions in cutaneous T-cell lymphoma
Xu S, Weiss E, Singh K, Damsky W, Girardi M. A case of bullous lesions in cutaneous T-cell lymphoma. JAAD Case Reports 2023, 35: 90-93. PMID: 37223111, PMCID: PMC10201206, DOI: 10.1016/j.jdcr.2023.02.026.Peer-Reviewed Original ResearchIntegrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations
Ren J, Qu R, Rahman N, Lewis J, King A, Liao X, Mirza F, Carlson K, Huang Y, Gigante S, Evans B, Rajendran B, Xu S, Wang G, Foss F, Damsky W, Kluger Y, Krishnaswamy S, Girardi M. Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations. Blood Advances 2023, 7: 445-457. PMID: 35947128, PMCID: PMC9979716, DOI: 10.1182/bloodadvances.2022008168.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMalignant CTCL cellsDiverse transcriptomic profilesT cellsSingle-cell RNACTCL cellsDevelopment of CTCLIntegrated transcriptomeT-cell receptor sequencingT cell exhaustion phenotypeCommon antigenic stimulusPeripheral blood CD4Transcriptomic profilesGene expressionT-cell lymphomaIntegrative analysisPotential therapeutic targetProliferation advantageLimited diversityBlood CD4Blood involvementMutation levelsExhaustion phenotypeWorse prognosisAntigenic stimulusA rare presentation of cutaneous T-cell lymphoma mimicking morphea
Yu B, Kim R, Roy S, Girardi M. A rare presentation of cutaneous T-cell lymphoma mimicking morphea. JAAD Case Reports 2023, 33: 59-61. PMID: 36860808, PMCID: PMC9969200, DOI: 10.1016/j.jdcr.2023.01.007.Peer-Reviewed Original ResearchProteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells
Xu S, Ren J, Lewis J, Carlson K, Girardi M. Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells. Journal Of Investigative Dermatology 2023, 143: 1322-1325.e3. PMID: 36642402, DOI: 10.1016/j.jid.2022.12.017.Peer-Reviewed Original Research
2022
Treatment of toxic epidermal necrolysis and concurrent COVID-19-associated hyperinflammatory syndrome with systemic corticosteroids and etanercept
Choi R, Garritano J, Laird M, Johnston M, Tkachenko E, Damsky W, Little AJ, McNiff J, Girardi M, Nelson CA. Treatment of toxic epidermal necrolysis and concurrent COVID-19-associated hyperinflammatory syndrome with systemic corticosteroids and etanercept. JAAD Case Reports 2022, 29: 139-141. PMID: 36160836, PMCID: PMC9485430, DOI: 10.1016/j.jdcr.2022.09.009.Peer-Reviewed Case Reports and Technical NotesEfficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Kim EJ, Mangold AR, DeSimone JA, Wong HK, Seminario-Vidal L, Guitart J, Appel J, Geskin L, Lain E, Korman NJ, Zeitouni N, Nikbakht N, Dawes K, Akilov O, Carter J, Shinohara M, Kuzel TM, Piette W, Bhatia N, Musiek A, Pariser D, Kim YH, Elston D, Boh E, Duvic M, Huen A, Pacheco T, Zwerner JP, Lee ST, Girardi M, Querfeld C, Bohjanen K, Olsen E, Wood GS, Rumage A, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH, Poligone B. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides). JAMA Dermatology 2022, 158: 1031-1039. PMID: 35857290, PMCID: PMC9301595, DOI: 10.1001/jamadermatol.2022.2749.Peer-Reviewed Original ResearchConceptsT-cell lymphomaAdverse eventsHypericin-photodynamic therapyIndex lesionClinical trialsEarly-stage cutaneous T-cell lymphomaMycosis fungoides cutaneous T-cell lymphomaActive drugCommon treatment-related adverse eventsDrug-related serious adverse eventsResponse rateTreatment-related adverse eventsPhotodynamic therapyCutaneous T-cell lymphomaEnd pointLong-term adverse effectsLesion response ratePlaque-type lesionsPrimary end pointSecondary end pointsSerious adverse eventsWeeks of therapySignificant clinical responseApplication site reactionsWeeks of treatmentFactors Associated With In-Hospital Mortality in Mycosis Fungoides Patients: A Multivariable Analysis
King ALO, Lee V, Mirza FN, Jairam V, Yang DX, Yu JB, Park HS, Girardi M, Wilson LD, An Y, Wilson L. Factors Associated With In-Hospital Mortality in Mycosis Fungoides Patients: A Multivariable Analysis. Cureus 2022, 14: e28043. PMID: 36120198, PMCID: PMC9474264, DOI: 10.7759/cureus.28043.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaNationwide Emergency Department SampleHospital mortalityMycosis fungoides patientsMycosis fungoidesMF patientsBackground Mycosis fungoidesIn-Hospital MortalitySpecific clinical factorsMultivariable logistic regressionEmergency Department SampleT-cell lymphomaUnderstanding of patientsSézary syndromeClinical factorsIndolent courseMultivariable analysisSurvival outcomesFemale sexHospital characteristicsAdvanced ageEmpirical managementPatientsMF casesGreater riskComment on “Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab”
Cohen JM, Damsky W, Girardi M. Comment on “Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab”. Journal Of The American Academy Of Dermatology 2022, 87: e241-e242. PMID: 35933070, DOI: 10.1016/j.jaad.2022.05.069.Peer-Reviewed Original Research